Dow Jones
36 117,38 +62,95 (+0,17 %) Nasdaq
14 339,99 +193,28 (+1,37 %) Nikkei 225
32 363,57 -494,74 (-1,51 %) EUR/USD
1,0790 -0,0008 (-0,08 %) HANG SENG
16 306,58 -39,31 (-0,24 %) Bitcoin EUR
40 322,09 -410,16 (-1,01 %)
MRK Jan 2026 80.000 call
| Clôture précédente | 26,50 |
| Ouverture | 27,50 |
| Offre | 28,20 |
| Vente | 29,25 |
| Prix d’exercice | 80,00 |
| Date d’expiration | 2026-01-16 |
| Var. jour | 27,50 - 27,50 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 10 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
